What Are Antiprotozoal Drugs & How Do They Work?

Antiprotozoal drugs are medicines designed to kill or disable single-celled parasites called protozoa, organisms responsible for some of the world’s deadliest and most widespread infectious diseases, including malaria, sleeping sickness, leishmaniasis, and amoebic dysentery. Unlike bacteria, protozoa are complex cells with nuclei and specialized internal structures, which makes developing drugs against them trickier than developing conventional antibiotics. The way these drugs work varies enormously: some poison a parasite’s ability to detoxify its own waste, others starve it of essential vitamins, and still others punch holes in its cell membrane. Understanding the different classes of antiprotozoal drugs and the strategies behind them reveals why treating parasitic infections remains one of the more challenging problems in medicine.

The Parasites These Drugs Target

Protozoa are a sprawling group, and only a fraction cause human disease. The ones that matter most include Plasmodium species (the cause of malaria), Trypanosoma species (responsible for sleeping sickness in Africa and Chagas disease in the Americas), Leishmania (transmitted by sandflies), Entamoeba histolytica (which causes amoebic dysentery), Giardia lamblia (a waterborne gut parasite familiar to hikers and travelers), and Toxoplasma gondii, which is estimated to infect somewhere between 20 and 50 percent of the world’s population.¹ Each of these parasites has a different life cycle, occupies different tissues, and exploits different metabolic pathways, which is why there is no single antiprotozoal drug that works against all of them. Malaria parasites live inside red blood cells; Leishmania hides inside immune cells called macrophages; Trypanosoma cruzi burrows into heart muscle. A drug that reaches one of those hiding places may never reach the others.

Quinolines and the Heme Detoxification Trick

The oldest and best-known class of antiprotozoals is the quinoline family, which includes chloroquine, mefloquine, quinine, and amodiaquine. These drugs target the malaria parasite specifically, and they exploit a peculiar vulnerability in the parasite’s feeding habits. Plasmodium parasites consume hemoglobin from red blood cells as a food source, but digesting hemoglobin releases free heme, a molecule that is highly toxic to the parasite. To survive, the parasite converts free heme into an inert crystal called hemozoin. Quinoline drugs block that crystallization process, causing toxic heme to accumulate and kill the parasite from the inside.

Research shows that chloroquine inhibits hemozoin crystallization by binding to the growing crystal surfaces. A concentration of just 2 micromolar of chloroquine is enough to completely arrest crystal growth, a figure roughly ten thousand times lower than the concentration of heme the parasite produces during digestion.² Among the quinolines, chloroquine and quinacrine are the most potent inhibitors, while quinine and mefloquine are less active but still effective.³ The drugs slow heme crystallization rather than irreversibly blocking it, meaning the effect is dose-dependent: higher drug concentrations leave more free heme circulating inside the parasite, doing more damage.⁴

Artemisinin and Iron-Fueled Free Radicals

Artemisinin, derived from a Chinese medicinal plant, works through a completely different mechanism than quinolines. The drug contains an unusual chemical bridge involving two oxygen atoms, called an endoperoxide. When artemisinin comes into contact with iron, which is abundant inside malaria-infected red blood cells, the iron catalyzes the breakup of that bridge, generating highly reactive free radicals. Those radicals tear through the parasite’s proteins and membranes indiscriminately.⁵ The drug essentially weaponizes the parasite’s own iron-rich environment against it.

Artemisinin-based combination therapies, known as ACTs, pair an artemisinin derivative with a longer-acting partner drug and are the frontline treatment for malaria worldwide. The artemisinin component kills parasites fast, within hours, while the partner drug mops up survivors over the next several days. This pairing also helps slow the emergence of resistance, since parasites would need to develop defenses against both drugs simultaneously.

Antifolates and Starving Parasites of a Key Vitamin

Folate, a B vitamin, is essential for building DNA. Humans get folate from food, but many protozoa, especially Plasmodium, must manufacture their own. Antifolate drugs exploit this difference by blocking two key enzymes in the parasite’s folate-manufacturing pathway: dihydrofolate reductase and dihydropteroate synthase.⁶ Without folate, the parasite cannot replicate its DNA and dies.

Pyrimethamine is the best-known drug in this class. It is used against both malaria and toxoplasmosis, since Toxoplasma gondii also depends on its own dihydrofolate reductase enzyme.⁷ Pyrimethamine is typically combined with a sulfonamide drug, such as sulfadoxine, to hit both enzymes at once. The combination is synergistic: blocking two steps in the same pathway is far more effective than blocking either one alone. Because humans absorb folate from their diet rather than synthesizing it through these enzymes, the drugs are relatively selective, though high doses can still interfere with human folate metabolism, which is why folate supplements are sometimes given alongside treatment.

Nitroimidazoles and the Oxygen-Starved Parasites

Metronidazole, the flagship drug in this class, is the go-to treatment for infections caused by anaerobic protozoa like Giardia, Entamoeba histolytica, and Trichomonas vaginalis. These parasites thrive in low-oxygen environments and rely on unusual energy-producing enzymes that most human cells do not use. One such enzyme, pyruvate:ferredoxin oxidoreductase, activates metronidazole by converting it into a toxic form that damages the parasite’s DNA.⁸

The selectivity here is elegant. Human cells use oxygen-dependent pathways to generate energy and lack the specific enzyme that activates metronidazole, so the drug remains inert in human tissue. Only inside an anaerobic parasite does it become weaponized. This is why metronidazole works so well against gut and genital protozoa that live in oxygen-poor niches but has no effect on malaria parasites, which live inside well-oxygenated red blood cells.

Membrane-Disrupting Drugs for Leishmaniasis

Leishmania parasites present a unique therapeutic challenge because they live inside macrophages, the very immune cells that are supposed to destroy invaders. One of the most effective drugs against visceral leishmaniasis is amphotericin B, originally an antifungal. The drug binds to ergosterol, a component of the Leishmania cell membrane that is absent in human cells (which use cholesterol instead). By binding ergosterol, amphotericin B disrupts membrane integrity, causing ions to leak out and ultimately killing the parasite.⁹

Liposomal formulations of amphotericin B, where the drug is packaged inside tiny fat bubbles, have improved safety dramatically. The lipid coating naturally directs the drug toward the liver and spleen, where Leishmania concentrates, and reduces the kidney damage that older formulations caused. This is one of the few cases in antiprotozoal medicine where improving the delivery vehicle was almost as important as finding the right drug.

Targeting the Parasite’s Ribosomes

Some antiprotozoal drugs work by disrupting protein synthesis at the parasite’s ribosomes, the cellular machinery that translates genetic instructions into functional proteins. Paromomycin, an aminoglycoside antibiotic, binds to the ribosome’s decoding center in Leishmania parasites and causes translation errors, essentially garbling the genetic messages so the cell produces defective proteins.¹⁰ The drug binds to a specific site on the small ribosomal subunit and forces two key molecular residues into a locked position, which tricks the ribosome into accepting the wrong building blocks during protein assembly.

What makes this approach viable against a eukaryotic parasite, despite the fact that human cells also have ribosomes, is that the Leishmania ribosome’s binding pocket is structurally much closer to a bacterial ribosome than to a human one. Paromomycin significantly decreases protein synthesis in Leishmania cell-free systems while having a much weaker effect on mammalian ribosomes.¹¹ This differential susceptibility is what gives the drug its therapeutic window. The drug is now used topically and by injection for various forms of leishmaniasis.

Shutting Down the Parasite’s Power Supply

Atovaquone takes yet another approach: it targets the parasite’s mitochondria. Specifically, it inhibits the cytochrome bc1 complex, a critical component of the electron transport chain that parasites use to generate energy.¹² When this complex is blocked, the mitochondrial membrane loses its electrical charge, and the organelle essentially shuts down.¹³

Atovaquone is used against both malaria (usually paired with proguanil, sold as Malarone) and against Pneumocystis and Toxoplasma infections in immunocompromised patients. The selectivity comes from structural differences between the parasite’s cytochrome bc1 complex and the human version: the drug fits snugly into the parasite’s enzyme but has poor affinity for ours. Resistance can emerge through mutations in the gene encoding cytochrome b, which alter the drug’s binding site.¹⁴ This is why atovaquone is almost always used in combination with another drug.

The Apicoplast, an Unusual Weak Spot

Malaria parasites and some related protozoa carry a tiny internal structure called an apicoplast, an organelle descended from an ancient photosynthetic alga that the parasite’s ancestor swallowed hundreds of millions of years ago. The apicoplast lost the ability to photosynthesize long ago, but it retained essential metabolic functions, including fatty acid and heme production, that the parasite cannot do without.¹⁵ Because the apicoplast’s internal machinery still resembles that of bacteria, conventional antibiotics can disrupt it.

Doxycycline, clindamycin, and azithromycin all have anti-apicoplast activity.¹⁶ These drugs interfere with protein synthesis, DNA replication, or specific metabolic pathways inside the apicoplast. The effect is unusual: parasites treated with apicoplast-targeting drugs often appear normal at first but produce offspring that are unable to survive, a phenomenon called “delayed death.”¹⁷ This delayed effect makes these antibiotics unsuitable for treating acute malaria on their own, but they work well as partner drugs or as prophylaxis for travelers. Doxycycline, for instance, is widely prescribed to prevent malaria in people visiting endemic areas.

Why Drug Resistance Keeps Winning

Resistance is the central challenge of antiprotozoal medicine. Protozoa reproduce rapidly and have large populations in infected individuals, which means that random mutations conferring drug resistance arise frequently and can spread under drug pressure. Chloroquine resistance in Plasmodium falciparum, which rendered the most affordable malaria drug largely ineffective across much of Africa and Southeast Asia, is driven by mutations in a transporter protein called PfCRT. Multiple point mutations in the gene encoding this transporter alter how the drug is handled inside the parasite’s digestive compartment, allowing the parasite to pump chloroquine out before it can accumulate enough to be lethal.¹⁸

Resistance mechanisms differ from drug to drug. For metronidazole, Giardia and Trichomonas can develop resistance by downregulating the activating enzyme, so the drug is never converted to its toxic form.⁸ For atovaquone, single amino acid changes in cytochrome b can be enough to block drug binding.¹⁴ For paromomycin, resistant Leishmania strains show increased production of ribosomal proteins, apparently compensating for the drug’s interference with translation.¹⁹ The diversity of resistance strategies underscores why combination therapy, using two or more drugs with different mechanisms, has become standard practice in treating malaria and is increasingly advocated for other protozoal infections.

Blocking Transmission, Not Just Treating Illness

Most antiprotozoal drugs are designed to clear an infection and make a patient better. But for diseases transmitted by insect vectors, there is growing interest in drugs that can also stop the parasite from spreading to the next person. In malaria, this means targeting gametocytes, the sexual stage of the parasite that a mosquito picks up when it bites an infected person. Drugs that kill or inhibit gametocytes could amplify the impact of other control measures by breaking the transmission cycle.²⁰

Not all antimalarials are equally good at this. Some drugs that effectively treat symptomatic malaria have little impact on mature gametocytes. In feeding experiments using natural parasite isolates from West Africa, most compounds tested reduced mosquito infection rates in a dose-dependent way, though certain drugs like dihydroartemisinin and ferroquine were exceptions and did not reduce infection rates.²¹ Primaquine and its newer relative tafenoquine are among the few drugs with strong activity against mature gametocytes, which is why the World Health Organization recommends adding a single low dose of primaquine to standard malaria treatment in areas pursuing elimination.

Getting Drugs Where They Need to Go

One of the toughest practical problems in antiprotozoal medicine is drug delivery. Some protozoa infect tissues that are notoriously hard for drugs to reach. The most dramatic example is late-stage sleeping sickness, caused by Trypanosoma brucei, where the parasite crosses the blood-brain barrier and infects the central nervous system. Treating it requires drugs that can also cross that barrier. Most molecules cannot: the brain is protected by tightly sealed blood vessels that exclude the majority of circulating compounds. Metronidazole is one of the few anti-infective drugs that achieves concentrations in cerebrospinal fluid nearly equal to those in blood, which is part of why nitroimidazole-class drugs have been explored for brain-stage trypanosomiasis.

Leishmaniasis presents a different access problem. The parasites live inside macrophages, so a drug must first enter the immune cell and then reach the compartment inside it where the parasite hides. Amphotericin B in its liposomal form exploits the natural tendency of macrophages to engulf lipid particles, essentially hitchhiking into the parasite’s hiding place. For other infections, like Chagas disease, the parasite takes up residence inside cardiac muscle cells, and reaching therapeutic drug levels in that tissue without unacceptable toxicity has limited treatment options for decades.

Drug Repurposing and the Pipeline for Neglected Diseases

Developing new antiprotozoal drugs from scratch is expensive, and the populations most affected by protozoal diseases are often the least able to pay for treatment. This economic reality has driven growing interest in drug repurposing, the strategy of testing drugs already approved for other conditions against parasitic protozoa.²² Because repurposed drugs have already passed safety testing in humans, they can reach patients years faster and at a fraction of the cost of a newly designed molecule.

Cryptosporidiosis is a case in point. Cryptosporidium, a protozoan that causes severe diarrhea and can be fatal in malnourished children and immunocompromised adults, currently has only one approved treatment: nitazoxanide, which shows limited effectiveness. The parasite’s unusual biology, including the lack of a mitochondrion and a reduced set of metabolic pathways, makes conventional drug targets scarce. Researchers have been turning to phenotypic screening, where large libraries of existing compounds are tested for their ability to kill the parasite in cell culture, and this approach has begun yielding a robust pipeline of candidates.²³ Several of the most promising leads originated as drugs or drug candidates for entirely different diseases.

Public-private partnerships like the Drugs for Neglected Diseases initiative and the Medicines for Malaria Venture have been instrumental in pushing antiprotozoal compounds through clinical trials that would otherwise never get funded. The results have been tangible: fexinidazole, the first all-oral treatment for sleeping sickness, was approved in 2018 after decades of effort to find an alternative to older drugs that required hospitalization and carried severe side effects. Progress is real, though slower than for diseases that primarily affect wealthier countries.